Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia

Formulary

Volumn 45, Issue 10, 2010, Pages 313-317

  Ehret, Megan J ^a   Sopko, Michael ^b   Lemieux, Tricia ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b TOURO COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; DILTIAZEM; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; OLANZAPINE; PLACEBO; PROLACTIN; RIFAMPICIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; TRIACYLGLYCEROL;

AKATHISIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FOOD INTAKE; HUMAN; HYPERPROLACTINEMIA; METABOLIC SYNDROME X; MOLECULAR WEIGHT; NAUSEA; ORTHOSTATIC HYPERTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE;

EID: 78651338122     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
2. Lieberman JA, Stroup TS, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
5. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
6. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119:171-179.
7. Green MF. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions [editorial]. Am J Psychiatry. 2007;164:992-994.
8. Keefe RSE, Sweeny JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early pyschosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1061-1071.
9. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115:4-11.
10. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18:1715-1726.
11. Ishiyama T, Loebel A, Cucchiaro J, et al. Comparative receptor binding profi le of lurasidone and other first and second generation antipsychotics [abstract]. Presented at American Psychiatric Association meeting, May 22- 26, 2010, New Orleans, LA. Abstract NR6-40.
12. Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci. 2004;25:481-486.
13. Suckling CJ, Murphy JA, Khalaf AI, et al. M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds. Bioorg Med Chem Lett. 2007;17:2649-2655.
14. Meneses A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res. 2004;155:275-282.
15. Guscott M, Bristow LJ, Hadingham K, et al. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology. 2005;48:492-502.
16. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829-836.
17. Loebel A, Cucchiaro J, Silva R, Ogasa M, Severs J, Marder S. Effi cacy of lurasidone in schizophrenia: results of a pooled post hoc factor analysis of four 6-week, placebocontrolled studies [abstract]. Presented at meeting of the American College of Neuropsychopharmacology, December 6-10, 2009; Hollywood, FL. Abstract 75.
18. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for axis I and II DSM-IV disorders, patient edition (SCIDIV/ P). New York: Biometrics Research, NY State Psychiatric Institute; 1996.
19. Dainippon Sumitomo Pharma Co., Ltd. Lurasidone Meeting, June 12, 2009. Available at: www.ds-pharma.com/ir/presentation/img/rd.2009.06.pdf. Accessed on October 22, 2010.
20. Meltzer H, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled PEARL 2 trial [abstract]. Presented at: American College of Neuropsychopharmacology; December 6-10, 2009; Hollywood, Fla. Abstract 76.
21. Clinical Trials.gov. Available at: www.clinicaltrials.gov. Accessed on October 19, 2010.
22. Cucchiaro J, Pikalov A, Ogasa M, et al. Safety of lurasidone: pooled analysis of fi ve placebocontrolled trials in patients with schizophrenia [abstract]. Presented at : the American Psychiatric Association; May 22-26, 2010; New Orleans, La. Abstract NR6-20.
23. Meyer J, Cucchiaro J, Pikalov A, Hsu J, Loebel A. Differential metabolic profi les of lurasidone and olanzapine: data from a 6-week, double-blind, placebo-controlled schizophrenia trial. Presented at: the American Psychiatric Association; May 22-26,2010; New Orleans, La. Abstract NR6-19.
24. Preskorn S, Chiu YY, Sarubbi D, Ogasa M, Cucciaro J, Loebel A. Lurasidone pharmacokinetics: assessment of potential for drug-drug interactions. Presented at: New Research Approaches for Mental Health Interventions; June 14-17, 2010; Boca Raton, Fla.Abstract 1-64.